Table 1 Characteristics of patients in the training and validation cohorts
Characteristic | Training Cohort | Validation Cohort | P-value |
|---|---|---|---|
Gender, n(%) | 0.570 | ||
male | 40 (65.6) | 18 (72.0) | |
female | 21 (34.4) | 7 (28.0) | |
Age (years) | 0.139 | ||
Mean | 58.64 | 60.25 | |
Range | 35–84 | 42–78 | |
T stage, n(%) | 0.818 | ||
T1 | 16 (26.2) | 6 (24.0) | |
T2 | 28 (45.9) | 14 (56.0) | |
T3 | 7 (11.5) | 1(4.0) | |
T4 | 10 (16.4) | 4 (16.0) | |
N stage, n(%) | 0.123 | ||
N0 | 9(14.8) | 7 (28.0) | |
N1 | 6 (9.8) | 2 (8.0) | |
N2 | 19 (31.1) | 9 (36.0) | |
N3 | 27 (44.3) | 7 (28.0) | |
M stage, n(%) | 0.576 | ||
M0 | 35 (57.4) | 16 (64.0) | |
M1 | 26 (42.6) | 9 (36.0) | |
Pathological subtype, n(%) | 0.394 | ||
Adenocarcinoma | 36 (59.0) | 17 (68) | |
Squamous cell carcinoma | 23 (37.7) | 8 (32) | |
Large cell lung cancer | 2 (3.3) | 0 (0) | |
Lymph nodes status, n(%) | 0.885 | ||
Positive | 99 (60.7) | 42 (61.8) | |
Negative | 64 (39.3) | 26 (38.2) |